The first ever phase III trials for multidrug-resistant TB (MDR-TB) finally yielded results. Treatment Action Group (TAG), ACTION, and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) presented the results in a webinar held on 12 December 2017. The webinar explored implications for the field, from the delamanid C213 trial and the STREAM trial to evaluate the shorter regimen for MDR-TB.

Exploring the implications of the delamanid phase III and STREAM trial results

Preliminary results from two phase III drug-resistant TB (DR-TB) clinical trials were presented at the 48th Union World Conference on Lung Health: stage 1 of the STREAM trial and the Otsuka 213 delamanid trial.

DR-TB STAT and the Sentinel Project will host a webinar, MDR-TB Treatment with Bedaquiline in Children and Adolescents: Global Recommendations and Program Experience in Belarus on 21 November 2017.

DR-TB STAT and the Sentinel Project will host a webinar, MDR-TB Treatment with Bedaquiline in Children and Adolescents: Global Recommendations and Program Experience in Belarus on 26 May 2017.

DR-TB STAT and the Sentinel Project will host a webinar on 7 April 2017, The Time Has Come: The Case for Injectable-Sparing Treatment Regimens for Children with MDR-TB.

The DR-TB Scale-Up Treatment Action Team (DR-TB STAT) issued a Bedaquiline Bulletin.

The DR-TB Scale-Up Treatment Action Team (DR-TB STAT) released its September 2016 update informing about the general progress in the introduction of bedaquiline and delamanid in TB programs worldwide.

The update informs about the general progress in the introduction of bedaquiline and delamanid in TB programs worldwide and reports on the requests made in the Call to Action issued in March 2015.